Bimekizumab: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
CSV import |
||
| Line 1: | Line 1: | ||
{{ | {{Short description|Monoclonal antibody used in the treatment of psoriasis}} | ||
| | {{Drugbox | ||
| verifiedfields = changed | |||
| | | verifiedrevid = 477002547 | ||
| | | image = Bimekizumab.png | ||
| | | width = 200px | ||
| type = mab | |||
| mab_type = mab | |||
| source = zu/o | |||
| target = IL-17A, IL-17F | |||
| | | tradename = Bimzelx | ||
| | | routes_of_administration = Subcutaneous | ||
| | | legal_status = Rx-only | ||
| | | atc_prefix = L04 | ||
| | | atc_suffix = AC21 | ||
| | | drugbank = DB15654 | ||
| | | chemspiderid = none | ||
| kegg = D11468 | |||
| legal_status | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| synonyms = | | synonyms = | ||
}} | }} | ||
'''Bimekizumab''' | '''Bimekizumab''' is a [[monoclonal antibody]] used in the treatment of [[psoriasis]] and other inflammatory conditions. It is marketed under the trade name '''Bimzelx'''. Bimekizumab works by selectively inhibiting the activity of [[interleukin-17A]] (IL-17A) and [[interleukin-17F]] (IL-17F), which are cytokines involved in inflammatory processes. | ||
==Mechanism of Action== | |||
Bimekizumab is a [[biologic therapy]] that targets and neutralizes IL-17A and IL-17F. These cytokines are part of the [[interleukin-17]] family, which plays a crucial role in the pathogenesis of [[autoimmune diseases]] such as psoriasis. By inhibiting these cytokines, bimekizumab reduces inflammation and the symptoms associated with psoriasis. | |||
==Clinical Use== | |||
Bimekizumab is primarily used for the treatment of moderate to severe [[plaque psoriasis]] in adults who are candidates for systemic therapy or [[phototherapy]]. It is administered via [[subcutaneous injection]]. | |||
==Administration== | |||
The recommended dosage of bimekizumab is an initial dose followed by maintenance doses at regular intervals. The specific dosing schedule may vary based on the patient's response and the prescribing physician's recommendations. | |||
==Side Effects== | |||
Common side effects of bimekizumab include [[upper respiratory tract infections]], [[headache]], and [[injection site reactions]]. Serious side effects may include increased risk of infections, such as [[tuberculosis]], and hypersensitivity reactions. | |||
==Contraindications== | |||
Bimekizumab is contraindicated in patients with known hypersensitivity to the drug or any of its components. It should be used with caution in patients with a history of chronic infections or those who are immunocompromised. | |||
==Related Pages== | |||
* [[Psoriasis]] | |||
* [[Monoclonal antibody therapy]] | |||
* [[Interleukin-17]] | |||
* [[Autoimmune disease]] | |||
[[Category:Monoclonal antibodies]] | [[Category:Monoclonal antibodies]] | ||
[[Category:Immunosuppressants]] | |||
[[Category:Psoriasis treatments]] | |||
Revision as of 19:18, 22 March 2025
Monoclonal antibody used in the treatment of psoriasis
| Bimekizumab | |
|---|---|
| File:Bimekizumab.png | |
| INN | |
| Drug class | |
| Routes of administration | Subcutaneous |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | Rx-only |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Bimekizumab is a monoclonal antibody used in the treatment of psoriasis and other inflammatory conditions. It is marketed under the trade name Bimzelx. Bimekizumab works by selectively inhibiting the activity of interleukin-17A (IL-17A) and interleukin-17F (IL-17F), which are cytokines involved in inflammatory processes.
Mechanism of Action
Bimekizumab is a biologic therapy that targets and neutralizes IL-17A and IL-17F. These cytokines are part of the interleukin-17 family, which plays a crucial role in the pathogenesis of autoimmune diseases such as psoriasis. By inhibiting these cytokines, bimekizumab reduces inflammation and the symptoms associated with psoriasis.
Clinical Use
Bimekizumab is primarily used for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. It is administered via subcutaneous injection.
Administration
The recommended dosage of bimekizumab is an initial dose followed by maintenance doses at regular intervals. The specific dosing schedule may vary based on the patient's response and the prescribing physician's recommendations.
Side Effects
Common side effects of bimekizumab include upper respiratory tract infections, headache, and injection site reactions. Serious side effects may include increased risk of infections, such as tuberculosis, and hypersensitivity reactions.
Contraindications
Bimekizumab is contraindicated in patients with known hypersensitivity to the drug or any of its components. It should be used with caution in patients with a history of chronic infections or those who are immunocompromised.
